Who Paid My Doc
Jeffrey Gitt
Neurology Phoenix, AZ Doctor of Osteopathy
NPI 1831370741 CMS profile 82916
3805 E Bell Rd Ste 5600, Phoenix, AZ 85032
General payments
$275,008
Research payments
$8,042
Ownership & investment interest
$0
Research they led as principal investigator
$1,476,124
Through program year 2025, Jeffrey Gitt of Phoenix, AZ is reported in the CMS Open Payments database as having received $275,008 across 1,004 general payments and $8,042 in research payments paid to them. Separately, studies naming them as principal investigator received $1,476,124 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $101 | 3 | |
| 2025 | Research | $3,098 | 1 | |
| 2024 | General | $389 | 4 | |
| 2024 | Research | $1,081 | 1 | |
| 2023 | General | $7,563 | 32 | |
| 2023 | Research | $396 | 1 | |
| 2022 | General | $34,369 | 207 | |
| 2022 | Research | $1,547 | 2 | |
| 2021 | General | $38,952 | 197 | |
| 2021 | Research | $1,920 | 2 | |
| 2020 | General | $56,359 | 209 | |
| 2019 | General | $137,274 | 352 |
Beside peers
- Jeffrey Gitt
- Neurology median
- Middle half of Neurology
- National median
In program year 2025, general payments to Jeffrey Gitt were reported at $101. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.
Show as a table
| Year | Jeffrey Gitt | Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $137,274 | $474 | $118–$2,177 | $163 |
| 2020 | $56,359 | $367 | $82–$2,309 | $114 |
| 2021 | $38,952 | $438 | $104–$2,547 | $132 |
| 2022 | $34,369 | $442 | $103–$2,388 | $149 |
| 2023 | $7,563 | $464 | $119–$2,312 | $160 |
| 2024 | $389 | $468 | $119–$2,323 | $164 |
| 2025 | $101 | $457 | $118–$2,344 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 51 billing codesPaid by Medicare
$2,225,496
Medicare patients
104
Services billed
76,934
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 63% | |
| Diabetes | 37% | |
| Ischemic heart disease | 35% | |
| Depression | 33% | |
| Chronic kidney disease | 31% | |
| Atrial fibrillation | 30% | |
| Osteoporosis | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, ocrelizumab, 1 mg J2350 | Office | 16 | 13,800 | $449,033 |
| Injection, dalbavancin, 5 mg J0875 | Office | 14 | 5,100 | $61,836 |
| Injection, methylprednisolone sodium succinate, 5 mg J2919 | Office | 17 | 700 | $160 |
| Injection, methylprednisolone sodium succinate, up to 125 mg J2930 | Office | 15 | 26 | $115 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 16 | 36 | $21 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,011 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology in Arizona
Related records
Neurology in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.